Pharmaceutical

EMA endorses AbbVie’s Skyrizi for ulcerative colitis

The EMA’s CHMP gave a positive opinion for Abbvie’s Skyrizi as the company bolsters its immunology pipeline.

Jun 2, 2024 - 04:00
EMA endorses AbbVie’s Skyrizi for ulcerative colitis
The EMA’s CHMP gave a positive opinion for Abbvie’s Skyrizi as the company bolsters its immunology pipeline.
Read the original article

Tags:

Previous Article

Dupixent gets closer to EU approval as the FDA delays its decision on COPD

Next Article

Manufacturing inspections down in China amid arrest fears and no access

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

What will it take to end health care worker burnout?

What will it take to end health care worker burnout?

Oct 26, 2023

UK MHRA approves Advanz Pharma antibiotic for complex infections

UK MHRA approves Advanz Pharma antibiotic for complex i...

Apr 7, 2024

SCDARIC-33 by Regeneron Pharmaceuticals for Refractory ...

May 17, 2024